Our News

Affinia Therapeutics to Present New Data on its AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th Annual American Society of Gene & Cell Therapy 2025 Annual Meeting

Affinia Therapeutics Appoints Hideo Makimura, M.D., Ph.D., as Chief Medical Officer

Affinia Therapeutics Announces Development Candidate for BAG3 DCM and Completion of Pre-IND Meeting with the FDA

Affinia Therapeutics and Forge Biologics Announce AAV cGMP Manufacturing Partnership to Advance Affinia Therapeutics’ Pipeline of Next-Generation Gene Therapies to the Clinic

ESGCT 2024: Affinia’s Proprietary AAV Plasmid Design Produces Industry Leading Manufacturability of Novel and WT Capsids

ESGCT 2024: In Vitro Binding to Human and NHP Orthologs of Candidate Receptors Identify Novel Systemically Delivered AAVs With Enhanced CNS Tropism

Discover what it’s like to be an Affinian

Changing the world for patients – powered by science